Grunenthal GmbH et al. vs Antecip Bioventures II LLC et al.

Final Written Decision

Granting Joint Motion to Limit the Petition

Joint Motion to Limit Petition

Order Conduct of the Proceeding

Hearing Transcript

Petitioner's Demonstrative Exhibits

Petitioner's Objections to Patent Owner's Demonstratives

Patent Owner's Argument Demonstrative Exhibits

Order - Setting New Start Time for Oral Argument

Order - Granting Patent Owner's Motion to Enter the Curriculum Vitae of Daniel L. Flamm, Sc.D. - 37 CFR 42.5

Petitioner's Request for Oral Argument

Patent Owner's Request for Oral Argument

Petitioner's Updated Mandatory Notices

Patent Owner's Objections to Petitioner's Reply Evidence

Declaration of David Brayden Ph.D.

CV of David Brayden Ph.D.

Deposition Transcript of Dr. Socrates E. Papapoulos

Welling

Dalle Carbonare, et al.

Petitioner's Reply

Shargel & Yu

Hill & Rang (2013)

Yamada, et al.

Hatton, et al.

Riviere, et al.

Lui, et al.

Dressman

Pazianas, et al.

Holm, et al.

Petitioner's Second Amended Exhibit List

DECISION Granting Motions for Pro Hac Vice Recognition of James R. Tyminski Jr. and Ms. Melinda R. Roberts

Notice of Stipulation Regarding Schedule

Declaration in Support of Petitioner's Motion for Pro Hac Vice Admission of James R. Tyminski Jr. Under 37 C.F.R. 42.10

Petitioner's Motion for Pro Hac Vice Admission of James R. Tyminski Jr. Under 37 C.F.R. 42.10

Petitioner's Motion for Pro Hac Vice Admission of Melinda R. Roberts Under 37 C.F.R. 42.10

Declaration in Support of Petitioner's Motion for Pro Hac Vice Admission of Melinda R. Roberts Under 37 C.F.R. 42.10

Petitioner's First Amended Exhibit List

Petitioner's Notice of Deposition of Dr. Socrates E. Papapoulos

Notice of Stipulation Concerning Extension of Due Date 2

Exhibit 2015

Patent Owner's Response

Exhibit 2016

Exhibit 2017

Exhibit 2018

Exhibit 2019

Exhibit 2020

Exhibit 2021

Exhibit 2022

Exhibit 2023

Exhibit 2024

Exhibit 2025

Exhibit 2026

Patent Owner's Exhibit List

Patent Owner's Power of Attorney

Patent Owner's Updated Mandatory Notices

Exhibit 2014

Patent Owner's Unopposed Motion for Withdrawal of Counsel

Order Conditionally Granting Patent Owner¿¿¿s Motions for Pro Hac Vice Admission of Michael Katz

Michael Katz

Declaration of Michael Katz in Support of Motion for Pro Hac Vice

Petitioner's Objections to Evidence

Patent Owner's Power of Attorney

Patent Owner's Updated Mandatory Notice

Patent Owner's Objections to Exhibits

Trial Instituted Document

Exhibit 3001

Exhibit 3002

Scheduling Order

Patent Owner's Preliminary Response

2001

Ex. 2002

Ex. 2003

Ex. 2005

Ex. 2006

Ex. 2008

Ex. 2010

Ex. 2011

Ex. 2004

Ex. 2007

Ex. 2009

Ex. 2012

Ex. 2013

Notice of Accord Filing Date

Patent Owner's Mandatory Notices

Patent Owner's Power of Attorney

Petitioner's Power of Attorney in Post Grant Review

U.S. Patent Pub. No. 2004/63670 (Fox)

U.S. Provisional App. No. 61/655,527 (¿¿¿the ¿¿¿527 provisional¿¿¿)

U.S. Provisional App. No. 61/803,721 (¿¿¿the ¿¿¿721 provisional¿¿¿)

U.S. App. No. 13/894,274 File History, Pages 301-600

U.S. App. No. 13/894,274 File History, Pages 601-800

U.S. App. No. 13/894,274 File History, Pages 2451-2724

Curriculum vitae of Dr. Stephen Bruehl, Ph.D.

U.S. Patent No. 9,283,239

D.H. Manicourt, et al., ¿¿¿Role of Alendronate Therapy for Posttraumatic Complex Regional Pain Syndrome Type I of the Lower Extremity,¿¿¿ 50(11) Arthritis & Rheumatism 3690 (Nov. 2004) (¿¿¿Manicourt¿¿¿)

A.P.C. de Castro, et al., ¿¿¿Zoledronic acid to treat complex regional pain syndrome type I in adult: case report,¿¿¿ 12(1) Rev. Dor. Sao Paulo 71 (Mar. 2011) (¿¿¿de Castro¿¿¿)

Catherine McHugh, Thomas Leonard, et al., ¿¿¿MER-101 tablets: A pilot bioavailability study of a novel oral formulation of zoledronic acid,¿¿¿ Molecular Cancer Therapeutics, Volume 6, Issue 11 Supplement pp. B194 (November 2007) (¿¿¿McHugh¿¿¿)

U.S. App. No. 14/635,857 (¿¿¿the ¿¿¿857 Application¿¿¿) File History

U.S. Provisional App. No. 61/646,538 (¿¿¿the ¿¿¿538 provisional¿¿¿)

U.S. Provisional App. No. 61/647,478 (¿¿¿the ¿¿¿478 provisional¿¿¿)

U.S. Provisional App. No. 61/654,292 (¿¿¿the ¿¿¿292 provisional¿¿¿)

U.S. Provisional App. No. 61/654,383 (¿¿¿the ¿¿¿383 provisional¿¿¿)

U.S. Provisional App. No. 61/655,541 (¿¿¿the ¿¿¿541 provisional¿¿¿)

U.S. Provisional App. No. 61/762,225 (¿¿¿the ¿¿¿225 provisional¿¿¿)

U.S. Provisional App. No. 61/764,563 (¿¿¿the ¿¿¿563 provisional¿¿¿)

U.S. Provisional App. No. 61/767,647 (¿¿¿the ¿¿¿647 provisional¿¿¿)

U.S. Provisional App. No. 61/767,676 (¿¿¿the ¿¿¿676 provisional¿¿¿)

U.S. App. No. 13/894,274 (abandoned after Final Rejection in favor of Continuing App. No. 15/014,994) (¿¿¿the ¿¿¿274 application¿¿¿) File History, Pages 1-300

U.S. App. No. 13/894,274 File History, Pages 801-1000

U.S. App. No. 13/894,274 File History, Pages 1001-1300

U.S. App. No. 13/894,274 File History, Pages 1301-1600

Declaration of Dr. Stephen Bruehl, Ph.D.

U.S. App. No. 13/894,274 File History, Pages 1601-1900

U.S. App. No. 13/894,274 File History, Pages 1901-2200

U.S. App. No. 13/894,274 File History, Pages 2201-2450

U.S. App. No. 14/063,979

U.S. App. No. 14/279,232

U.S. Patent No. 7,704,977

G.D. Schott, ¿¿¿Bisphosphonates for pain relief in reflex sympathetic dystrophy?¿¿¿ 350 The Lancet: Commentary (October 18, 1997). (¿¿¿Schott¿¿¿)

S. Adami, et al., ¿¿¿Bisphosphonate therapy of reflex sympathetic dystrophy syndrome,¿¿¿ 56(201-204) Annals of the Rheumatic Diseases (1997). (¿¿¿Adami¿¿¿)

J.F. Maillefert, et al.,¿¿¿Treatment of refractory reflex sympathetic dystrophy with pamidronate,¿¿¿ 54(687) Ann. Rheum. Dis.(1995). (¿¿¿Maillefert¿¿¿)

B. Cortet, et al., ¿¿¿Treatment of severe, recalcitrant reflex sympathetic dystrophy: assessment of efficacy and safety of the second generation bisphosphonate pamidronate,¿¿¿ 16(1) Clinical rheumatology (1997). (¿¿¿Cortet¿¿¿)

J.N. Robinson, et al., ¿¿¿Efficacy of pamidronate in complex regional pain syndrome type I,¿¿¿ 5(3) Pain Medicine (2004). (¿¿¿Robinson¿¿¿)

U.S. Patent No. 9,216,168

U.S. Patent No. 9,408,862

K. Siminoski, et al.,¿¿¿Intravenous pamidronate for treatment of reflex sympathetic dystrophy during breast feeding,¿¿¿ 15(10) Journal of Bone and Mineral Research (2000). (¿¿¿Siminoski¿¿¿)

Kubalek, et al., ¿¿¿Treatment of reflex sympathetic dystrophy with pamidronate: 29 cases,¿¿¿ 40 Rheumatology 1394-1397 (2001). (¿¿¿Kubalek¿¿¿)

H. Merskey and N. Bogduk, Classification of Chronic Pain: Descriptions of Chronic Pain Syndromes and Definitions of Pain Terms, 2nd ed. IASP Press (1994). (¿¿¿Merskey and Bogduk¿¿¿)

R.N. Harden, et al., ¿¿¿Validation of proposed diagnostic criteria (the ¿¿¿¿¿¿Budapest Criteria¿¿¿) for Complex Regional Pain Syndrome,¿¿¿ 150 Pain 268-274 (2010).

G.J. Bennett and Y.K. Xie, ¿¿¿A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man,¿¿¿ 33 Pain 87-107 (1988).

M. Daeman, et al., ¿¿¿Neurogenic Inflammation and Reflex Sympathetic Dystrophy,¿¿¿ 64(4) Acta Orthopaedica Belgica (1998).

Z. Seltzer, R. Dubner, and Y. Shir, ¿¿¿A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury,¿¿¿ 43 Pain 205-218 (1990).

S. Bruehl, ¿¿¿An Update on the Pathophysiology of Complex Regional Pain Syndrome,¿¿¿ 113 Anesthesiology 713-725 (2010).

S. Bruehl, et al., ¿¿¿External validation of IASP diagnostic criteria for Complex Regional Pain Syndrome and proposed research diagnostic criteria 81 Pain 147-154 (1999).

J. Zaspel, et al., ¿¿¿Treatment of early stage CRPS I ¿¿¿ cortisone (methylprednisolone) versus bisphosphonate (zoledronic acid),¿¿¿ (October 9, 2007) (¿¿¿Zaspel¿¿¿)

Petition for Post Grant Review of U.S. Patent No. 9,283,239